rct
    2009
    High Quality

    Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial

    Snitz BE, O'Meara ES, Carlson MC, Arnold AM, Ives DG, Rapp SR

    Published in JAMA

    Methodology

    Double-blind placebo-controlled trial (Ginkgo Evaluation of Memory study), 120 mg EGb761 twice daily vs placebo, median 6.1 years follow-up

    Key Findings

    Ginkgo biloba did not slow the rate of decline in memory, attention, visuospatial ability, language or executive function compared with placebo.

    Conclusions

    Standardised ginkgo extract does not slow age-related cognitive decline in community-dwelling older adults.

    Limitations

    Participants largely cognitively normal at baseline; adherence declined over the long follow-up.

    Supplements Studied

    Compared with placebo, the use of G. biloba, 120 mg twice daily, did not result in less cognitive decline in older adults with normal cognition or with mild cognitive impairment.

    Outcomes Measured

    Ginkgo biloba, 120 mg twice daily, did not result in less cognitive decline over a median of 6.1 years of follow-up.

    Ginkgo biloba did not slow the rate of decline in memory, attention, visuospatial ability, language or executive function compared with placebo.

    Related Health Concerns

    Study Details

    Year:2009
    Sample Size:3,069
    Duration:317 weeks
    Quality Score:9/10

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.